How to Choose a GLP-1 Provider After the FDA Crackdown

The compounded GLP-1 landscape looks dramatically different than it did a year ago. The FDA’s decision to end the semaglutide shortage in February 2025—followed by 503A enforcement in April 2025 and 503B enforcement in May 2025—reshuffled the entire market.

Some providers shut down. Some pivoted. And some were already doing things right and barely missed a beat. The providers that survived the crackdown are, by definition, the ones that built their operations on solid regulatory footing. That makes 2026 a better time than 2024 to find a trustworthy GLP-1 provider—you just need to know what to look for.

What Changed After the Crackdown

When the FDA declared the semaglutide shortage resolved on February 21, 2025, it triggered a regulatory countdown. Section 503A pharmacies had until April 22, 2025, to wind down compounded semaglutide production (a 60-day grace period). Section 503B outsourcing facilities had until May 22, 2025.

For tirzepatide, the shortage ended even earlier—October 2, 2024—with 503B enforcement beginning March 19, 2025.

The providers that survived either transitioned to compliant formulations, secured legal standing through modified salt forms (semaglutide sodium vs. semaglutide base), or operated 503B facilities with FDA registration that provided additional legal arguments for continued compounding.

Your Provider Vetting Checklist

1. Verify the Pharmacy

Every legitimate provider works with a licensed compounding pharmacy. You should be able to verify:

• State pharmacy license: Searchable on the state board of pharmacy website
• 503A or 503B classification: 503B facilities are FDA-registered and subject to federal inspections; 503A facilities are state-regulated
• LegitScript certification: An independent verification service used by Google, Facebook, and Amazon to confirm pharmacy legitimacy
• PCAB accreditation: The gold standard for compounding pharmacy quality (optional but a strong positive signal)

2. Confirm the Medical Evaluation

A legitimate provider requires a medical evaluation before prescribing. This doesn’t mean a lengthy in-person visit—telehealth consultations are perfectly appropriate—but it does mean more than a 30-second questionnaire.

Look for providers that ask about your medical history, current medications, allergies, BMI, previous weight loss attempts, and cardiovascular risk factors. Some will require lab work. All of this is normal and indicates a provider that takes prescribing seriously.

3. Understand the Pricing Structure

Transparent pricing means knowing exactly what you’ll pay each month. Watch out for:

• Subscription traps: Some providers lock you into 3–6 month commitments with auto-renewal. Make sure you can cancel without penalty
• Separate consultation fees: Is the provider consultation included in the monthly price, or is it billed separately?
• Shipping costs: Some providers charge $10–30 per shipment on top of the medication price
• Dose-dependent pricing: Legitimate providers typically charge more for higher doses (the active ingredient costs more). Flat pricing across all dose levels can indicate lower-quality compounding

4. Ask About the Medication Itself

You have every right to know what you’re injecting. Good providers will tell you:

• The exact formulation (semaglutide base, semaglutide sodium, etc.)
• The concentration (e.g., 5mg/mL, 10mg/mL)
• Whether the medication contains additional ingredients (B12, L-carnitine, etc.) and why
• The name and location of the compounding pharmacy
• Beyond-use dating (how long the medication is stable after preparation)

5. Check for Ongoing Support

GLP-1 therapy isn’t a “set it and forget it” treatment. Look for providers that offer:

• Follow-up consultations (at least quarterly, ideally monthly during titration)
• Easy dose adjustments without requiring a full new evaluation
• Access to a care team (provider, pharmacist, or support staff) for questions
• Guidance on diet, exercise, and side effect management

What About Providers That Offer “Alternatives”?

After the crackdown, some providers pivoted to products marketed as “GLP-1 alternatives” or “natural GLP-1 boosters.” Be cautious. If a product doesn’t contain semaglutide or tirzepatide (or another actual GLP-1 receptor agonist), it isn’t a GLP-1 medication—regardless of how it’s marketed.

Some supplement-based “alternatives” contain berberine, chromium, or other ingredients that may modestly affect blood sugar but do not produce the weight loss results seen with prescription GLP-1 medications.

The Providers Who Survived Are Stronger

Here’s the encouraging reality: the FDA crackdown was a filter. Providers who were cutting corners, using unlicensed pharmacies, or selling without proper medical oversight are largely gone. The providers operating in 2026 had to invest in compliance, pharmacy partnerships, and legitimate medical oversight to survive.

That means the average quality of telehealth GLP-1 providers in 2026 is meaningfully higher than it was in 2024. You still need to do your homework—but the homework is easier now.

The Bottom Line

Choosing a GLP-1 provider in 2026 comes down to verification. Verify the pharmacy. Verify the medical process. Verify the pricing. If a provider is transparent about all three, you’re in good hands. If they hedge, hide, or make it hard to find answers—there are plenty of better options available.